Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454493 | 1.00 | DPP3 (0.57) | DPP3NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL31452913 | 0.91 | DPP3 (0.61) | DPP3OPRM1 | |
| SCHEMBL29963309 | 0.90 | DPP3 (0.64) | DPP3NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL30272514 | 0.89 | DPP3 (0.57) | DPP3NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL29498733 | 0.89 | DPP3 (0.63) | DPP3ECE1DPP4 | |
| SCHEMBL30310835 | 0.87 | DPP3 (0.57) | DPP3NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL31474499 | 0.87 | DPP4 (0.61) | DPP3NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30610091 | 0.87 | DPP3 (0.69) | DPP3NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL29648960 | 0.87 | DPP3 (0.69) | DPP3NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30827785 | 0.87 | DPP3 (0.60) | DPP3NTSR2NTSR1SORT1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024111590-A1 | COMPOSITION CONTAINING RAS INHIBITOR PEPTIDE | 一丸ファルコス株式会社 | 2024-05-30 | — | — | WO | claimed |
| US-20220227813-A1 | Ras INHIBITORY PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2022-07-21 | — | — | US | claimed |
| EP-3970801-A1 | RAS INHIBITORY PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2022-03-23 | — | — | EP | claimed |
| WO-2024111590-A1 | COMPOSITION CONTAINING RAS INHIBITOR PEPTIDE | 一丸ファルコス株式会社 | 2024-05-30 | — | — | WO | disclosed |
| US-20220227813-A1 | Ras INHIBITORY PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3970801-A1 | RAS INHIBITORY PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227813-A1 | Ras INHIBITORY PEPTIDE | RSU1, RASGRP1, RASSF5 | DPP3 2838/4885NTSR2 134/4885NTSR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.